In vitro genotoxicity assessment routinely employs an exogenous metabolic activation mixture to simulate mammalian metabolism. Activation mixtures commonly contain post-mitochondrial liver supernatant (i.e. S9) from chemically induced Sprague Dawley rats. Although Organization for Economic Cooperation and Development (OECD) test guidelines permit the use of other S9 preparations, assessments rarely employ human-derived S9. The objective of this study is to review and evaluate the use of human-derived S9 for in vitro genetic toxicity assessment. All available published genotoxicity assessments employing human S9 were compiled for analysis. To facilitate comparative analyses, additional matched Ames data using induced rat liver S9 were obtained for certain highly cited chemicals. Historical human and induced rat S9 quality control reports from Moltox were obtained and mined for enzyme activity and mutagenic potency data. Additional in vitro micronucleus data were experimentally generated using human and induced rat S9. The metabolic activity of induced rat S9 was found to be higher than human S9, and linked to high mutagenic potency results. This study revealed that human S9 often yields significantly lower Salmonella mutagenic potency values, especially for polycyclic aromatic hydrocarbons, aflatoxin B1 and heterocyclic amines (~3-to 350-fold). Conversely, assessment with human S9 activation yields higher potency for aromatic amines (~2-to 50-fold). Outliers with extremely high mutagenic potency results were observed in the human S9 data. Similar trends were observed in experimentally generated mammalian micronucleus cell assays, however human S9 elicited potent cytotoxicity L5178Y, CHO and TK6 cell lines. Due to the potential for reduced sensitivity and the absence of a link between enzyme activity levels and mutagenic potency, human liver S9 is not recommended for use alone in in vitro genotoxicity screening assays; however, human S9 may be extremely useful in follow-up tests, especially in the case of chemicals with species-specific metabolic differences, such as aromatic amines.
Introduction
The noteworthy correlation between mutagenic and carcinogenic hazard has resulted in an understandable regulatory preoccupation with accurate detection of genetic toxicity and concomitant regulatory actions to protect human health. The routine screening of chemicals for genotoxic and/or mutagenic activity was first proposed more than half a century ago (1, 2) , and genotoxic events, such as gene mutations and chromosomal damage, are routinely assessed using a variety of in vitro and in vivo tests. The convenience and affordability of in vitro test systems for routine screening resulted in in vitro assays forming the cornerstone of most regulatory systems to assess genetic toxicity (2) . More recently, with efforts to conform to changes in the regulatory landscape worldwide [e.g. Seventh Amendment to the European Union (EU) Cosmetics Directive, Tox21, ToxCast, etc.], emphasis has shifted away from in vivo testing towards a greater, sometimes exclusive, emphasis on in vitro testing and predictive tools for human health risk assessment and regulatory decision-making (3) . The current in vitro battery of genetic toxicity assays employed by most regulatory agencies comprises a bacterial reverse mutation assay (Ames test), an in vitro mammalian cell gene mutation assay such as the mouse lymphoma assay (MLA) or the X-linked hypoxanthine-guanine phosphoribosyltransferase (HPRT) assay, and an in vitro mammalian cell chromosome damage assay such as the micronucleus (MN) or chromosome aberration (CA) test, and formerly, the sister chromatid exchange (SCE) assay (2) .
Metabolic activation is a crucial consideration in genetic toxicity testing. Due to the metabolic deficiencies of Salmonella typhimurium and other microorganisms, mammalian metabolic enzyme preparations, such as post-mitochondrial or 9000 × g tissue homogenate supernatants, generally dubbed S9, can be added to in vitro cultures to simulate in vivo xenobiotic activation and detoxification (4) . Rodent liver S9 is similarly used in in vitro mammalian cell genetic toxicity assays. In vitro mammalian cell genetic toxicity assays frequently utilise immortalised and/or transformed cell lines that are often metabolically deficient. Like the aforementioned prokaryotes, these cell lines are incapable of activating many promutagens in the absence of an exogenous metabolic enzyme preparation such as rodent liver S9.
S9 can be prepared from a variety of tissues; however, it is most often prepared from the liver, since this organ is associated with detoxification of xenobiotics via cytochrome P450 (CYP) catalysed reactions. Liver S9 from a variety of mammalian species has been used in genotoxicity assays, and although the molecular biology of xenobiotic-metabolising enzymes is widely conserved across mammals, there exist noteworthy species-, strain-and sex-specific differences (5) . These discrepancies can lead to significantly different responses in genotoxicity assays when using hepatic preparations from different sources (6) .
The most popular source of exogenous metabolic enzymes for in vitro genetic toxicity testing, by far, is S9 prepared from the livers of male Sprague-Dawley rats treated with enzyme-inducing agents such as Aroclor 1254 or a combination of ß-naphthoflavone and phenobarbital (7) . Aroclor 1254, a commonly used inducing agent, is a commercial mixture of polychlorinated biphenyls (PCBs) (4) that includes dioxin-like coplanar PCBs that are aryl hydrocarbon receptor (AhR) agonists, thus inducers of CYPs 1A1, 1A2 and 1B1, as well as non-coplanar PCBs that are constitutive androstane receptor (CAR) and pregnane X receptor (PXR) agonists, thus inducers of members of the CYP 2 and 3 families of enzymes. Alternative commercial PCB mixtures, such as Kaneclor 400, also exist. Phenobarbital and β-naphthoflavone, which are ligands of CAR and AhR, respectively, are often used to stimulate the production of CYPs in rodents such as the Sprague-Dawley rat prior to S9 preparation (9) . The use of the phenobarbital/β-naphthoflavone induction system permits avoidance of Aroclor 1254, which is a restricted agent in many countries. Other AhR ligands, such as 3-methylcholanthrene (3-MC) and 2,3,7,8-tetrachlorodibenzodioxin (TCDD), have also been utilised as enzyme inducers in genetic toxicology (8) .
Despite the convention to employ induced hepatic S9 from the rat, alternative activation systems are recommended for specific types of agents. For example, hepatic S9 from uninduced hamsters is frequently used for mutagenicity assessment of azo-compounds in a modified Ames test. The technique, which is sometimes referred to as the Prival assay, has been shown to be highly effective for the detection of mutagenic azo dyes (10) (11) (12) .
Although Aroclor 1254-induced rat S9 has become the standard for metabolic activation mixtures employed with in vitro genotoxicity assays, several concerns have arisen with respect to its routine use for genotoxicity assessment. The most serious concerns relate to the relevance of using a homogenised liver preparation from a chemically induced rodent to identify substances that may pose genotoxic risks to humans. In addition, the use of activation mixtures containing rat liver homogenate with cultured mammalian cell lines is hampered by marked cytotoxicity (13, 14) . In comparison with hepatic S9 from chemical-induced rodents, human liver S9 could be considered more relevant to the identification and assessment of human health hazards.
There are some obvious caveats associated with the use of human liver S9 for in vitro genetic toxicity assessment. For example, deviation from a system that employs controlled experimental animals could introduce uncontrolled variability across lots of humanderived S9. Humans, as a species, are extremely variable with respect to metabolic capacity, and factors such as age, sex and genotype are known to affect the ability to metabolise xenobiotics (15) . With respect to genotypic variability (i.e. genetic polymorphisms), fast and slow metaboliser phenotypes have been described for numerous enzymes, such as those in the CYP 1, 2 and 3 families, as well as N-acetyltransferases (NATs) and glutathione-S-transferases (GSTs). Many of the known polymorphisms have been associated with certain ethnic groups (16, 17) , and the differences are known to markedly impact the toxicity of xenobiotic substances and the efficacy of certain drugs.
In addition to variability associated with human polymorphisms, humans are also potentially exposed to a wide range of agents (e.g. foods, therapeutic products) that can modify the expression levels of hepatic enzymes. As such, the activity and expression of metabolic enzymes involved in the production of DNA-reactive substances can be expected to vary markedly from one individual to another. For example, tobacco smoke contains AhR agonists that induce CYPs 1A1, 1A2 and 1B1 expression, and many commonly consumed therapeutic agents are also known to significantly alter enzyme activity levels. The combination of genetic polymorphisms and exposures to substances that modify enzymatic activity levels results in selected sub-populations displaying elevated sensitivities to certain genotoxic agents (18) (19) (20) .
The International Life Sciences Institute/Health and Environmental Sciences Institute (ILSI/HESI) project committee on the Relevance and Follow-up of Positive Results in In Vitro Genetic Toxicity (IVGT) Testing, the predecessor of the Genetic Toxicology Technical Committee (GTTC), was tasked with investigating the causes of the low specificity associated with many in vitro genetic toxicity assessment tools (i.e. high frequency of false positives for animal carcinogenicity) (21) . Part of this international exercise involved evaluating options for improving the performance of existing test systems. For example, the project committee considered ways to standardise the source and handling of mammalian cell lines employed for genotoxicity assessment (22) . In addition, the committee was charged with evaluating the utility of exogenous activation systems containing human liver S9 in comparison with the conventional systems containing induced rat liver S9. The objective of this study is to review the available scientific literature pertaining to the use of human S9 for genetic toxicity assessment, and via the use of meta-analysis of published mutagenicity test results, as well as the generation of new experimental data, assess the utility of human S9, relative to induced rat liver S9, for in vitro genetic toxicity assessments. Since few studies employed human S9 for mammalian in vitro genotoxicity assessment, the new experimental data largely pertain to assessments in mammalian cells.
Materials and methods

Literature survey
Using the PubMed and Scopus databases, the scientific literature was rigorously searched to obtain all publications pertaining to the use of human liver S9 for genetic toxicity assessment (updated in December 2013). The search employed various combinations of the following search terms: human, S9, liver, hepatic, mutation, exogenous, metabolism, metabolic enzymes, post-mitochondrial supernatant, clastogen, strand break, DNA, micronucleus, HPRT, Ames, salmonella, mutagen, carcinogen and risk assessment. The overwhelming majority of published research on the topic pertains to the use of human S9 with the Salmonella reverse mutation assay; mutagenic potency data were collected from published studies and compiled in an Excel Workbook. In cases where the Salmonella mutagenicity results were only presented in figures, image analysis of digitised images was employed to regenerate the concentration-response data (e.g. GetData Graph Digitizer 2.26).
After the initial search for human S9 data, matching rat liver S9 results were collected for all chemicals wherein more than 10 mutagenic potency results, or observations, were collected for S. typhimurium (i.e. Ames test) strains employed in combination with human S9. Ten or more human S9 observations were found for 2-aminoanthracene (2-AA) in TA100, 2-aminofluorene (2-AF) in both TA100 and TA98, 3-MC in TA100, 2-acetylaminofluorene (2-AAF) in both TA100 and TA98, aflatoxin B1 (AFB1) in both TA100 and TA98, benzo[a]pyrene (BaP) in TA100, 2-amino-3-methylimidazo [4,5-f] quinolone (IQ) in TA98, 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine (PhIP) in TA98, and dimethylnitrosamine (DMN) in TA1535. For comparative purposes, approximately 20 Aroclorinduced rat hepatic S9 observations for each of these chemical-strain combinations were collected from the literature and the National Toxicology Program (NTP) database (23). The majority of the collected rat data was generated using S9 from Sprague-Dawley rats.
To critically examine the enzymatic profiles of Aroclor 1254-induced Sprague-Dawley rat liver S9; and moreover, to compare the profiles to those of human S9 preparations, we obtained historical quality control (QC) reports from Molecular Toxicology (Moltox) Inc. (Boone, NC, USA). The pooled human S9 QC reports contain information about human donors, including age, race, sex, cause of death, medical conditions, substance use and cold ischemia time. QC reports for both human-derived and Aroclor 1254-induced rat-derived liver S9 contain lot-specific alkoxyresorufin-O-deethylase (AROD) specific activity values (i.e. ng substrate per min per mg microsomal protein): more specifically ethoxyresorufin-O-deethylase (EROD), benzoxyresorufin-O-deethylase (BROD), methoxy-O-deethylase (MROD) and pentoxyresorufin-O-deethylase (PROD) specific activities. Additionally, these reports contained the results of Ames tests conducted using the specified S9 lot. The human S9 reports utilised BaP and 2-AA as positive controls, whereas Aroclor 1254-induced rat S9 reports utilised 6-aminochrysene (6-AC) and 2-AA.
Human liver S9 usage survey
A survey of 24 members of the Mammalian Mutagenicity Society, a special interest group associated with the Japanese Environmental Mutagenesis Society, was performed. This survey comprised 16 questions regarding the members' use of human liver S9 in genotoxicity testing in vitro (supplementary materials, available at Mutagenesis Online).
Test chemicals
All chemicals and reagents were purchased from Sigma/Aldrich Dorset UK, unless otherwise stated.
Metabolic activation
Sprague Dawley rat liver S9 was obtained from the hepatic microsomal fraction of Aroclor 1254-treated and untreated rats and provided by Molecular Toxicology Inc. (Boone, NC, USA). Human S9 was obtained from Molecular Toxicology Inc. and BD Biosciences (Oxford, UK). S9 was stored at −70°C or below until use. On the day of use, S9 mix was prepared by the addition of culture medium or buffers containing cofactors for NADPH generation to the S9 fraction. For Ames testing, the final S9 mix contained 4 mM NADP, 25 mM glucose-6-phosphate, 8 mM MgCl 2 , 33 mM KCl and 10% (v/v) S9 mix (24) . For human S9 experiments using mammalian cells, the S9 mix yielded final culture concentrations of 6 mM NADP and 24 mM isocitrate (25) . A final S9 concentration of 50 µL/plate was used in the Ames assay and 2% to 10% v/v was used for all mammalian cell tests.
Ames test
Standard plate incorporation assays were performed using S. typhimurium strains TA1535, TA1537, TA98 and TA100 and Escherichia coli strain WP2uvrA(pKM101) according to published methods (26) (27) (28) . All test compounds were dissolved in dimethyl sulphoxide (DMSO). In all tests, there were three plates for the control and each concentration of test compound. Plates were scored using a Perceptive Instruments Sorcerer image analyser.
Cell lines
All cell lines were confirmed to be mycoplasma free. /mL, respectively. Cultures were incubated for approximately 24 hr prior to preparation of microscope slides (29) .
As recommended in the Organization for Economic Cooperation and Development (OECD) test guideline 487, cytotoxicity was measured by Relative Population Doubling (RPD) as indicated below (30) . Preparation and scoring of slides for micronuclei enumeration CHO cells were trypsinised and counted using a haemocytometer. TK6 and L5178Y were also counted using a Coulter TM Counter. Microscope slides were prepared by centrifuging 2 × 10 4 cells in a Cytospin 3 (Shandon) centrifuge (200 × g for 8 min) and fixed with methanol. Slides were stained with acridine orange and scored at ×200 magnification using a Zeiss Axioplan microscope. All identified micronuclei were confirmed by eye to be separate and within the cytoplasm, to have an intact cytoplasmic membrane, and to be less than one third of the diameter of the main nucleus. Where possible, a total of at least 1000 cells per duplicate culture were scored.
Statistical analysis
All data analyses were carried out using SAS v.9.2 for Windows. Salmonella mutagenic potency values (i.e. the slope of the initial linear portion of the concentration-response function) for experimentally-generated data (i.e. 3-amino-1-methyl-5H-pyrido [4,3-b] indole [Trp-P2] and PhIP), and published concentration-response data obtained from the literature, were determined using ordinary least-squares linear regression. Comparisons of mean enzyme activity or mutagenic potency values across data groups (e.g. S9 source) were investigated using least-squares analysis of variance (ANOVA). Post hoc comparison of means across treatment groups employed Duncan's Multiple Range Test. In most cases, the values were log 10 transformed to equalise the variance across the groups and meet the assumptions of least squares ANOVA. Homogeneity of variance was evaluated using the Bartlett test, and the distribution of the residuals evaluated using the Kolmogorov-Smirnov test and visual inspection of a normal probability plot. For all observations obtained from Ames test data, results were deemed positive if a dose response was apparent, and the number of induced revertants reached at least two-fold the number of spontaneous. Contingency table analysis was used to examine the association between mutagenicity test outcome (i.e. positive or negative) and S9 source (i.e. rat or human). The statistical significance of the association was evaluated using the Pearson Chi-squared statistic. A Chi-square test with Yates-like modification was used to compare the induced frequency of micronucleated cells with matched negative controls, thereby evaluating statistical significance.
Results
Data collection
An extensive review of the scientific literature revealed 53 publications that employed human S9 preparations for in vitro mutagenicity assessment. The vast majority of these publications, 45 in total, describe the use of human S9 for Salmonella mutagenicity assessment, with only seven publications describing the use of human S9 for genotoxicity assessment in mammalian cells (i.e. MLA, HPRT, SCE, CA, MN and in vitro Comet; see supplementary Tables 1 and  2 , available at Mutagenesis Online). One publication described the use of human S9 in the bacterial umu assay. As described in the Materials and Methods section, an additional literature search was performed to collect approximately 20 matched Aroclor-induced rat liver S9 Ames test results for all chemicals wherein more than ten observations were found that used human liver S9 with a particular strain of S. typhimurium. This search yielded an additional 54 publications and 16 NTP reports.
Many of the publications found during the literature survey described the use of liver-derived S9 from other species, in addition to human. Wherever possible, mutagenic potency values associated with all S9 sources mentioned in the publications were collected from Salmonella mutagenicity studies or calculated from reported concentration-response data. In total, 1340 mutagenic potency values were obtained from the literature across 108 compounds tested in nine Ames test strains. An additional 10 Ames test results, comprising six human S9 and four rat S9 observations, were generated experimentally for PhIP and Trp-P2. Of the 1350 total observations, 678 utilised human S9, 312 utilised Aroclor 1254-induced rat S9, 106 utilised rat S9 induced by a combination of phenobarbital and β-naphthoflavone, 30 utilised rat S9 treated with other inducers (e.g. 3-MC or TCDD), 84 utilised uninduced rat S9, 40 utilised uninduced hamster S9, 18 utilised induced hamster S9, 29 utilised uninduced mouse S9, six utilised induced mouse S9, 17 utilised uninduced pig S9, 12 utilised uninduced monkey S9, 11 utilised uninduced rabbit S9, five utilised uninduced dog S9 and two utilised uninduced guinea pig S9.
Enzymatic activity profiles
Comparisons across lots of Moltox hepatic S9 were accomplished via the analysis of AROD activity values. Certain ethers of the fluorescent chemical resorufin are known to be metabolised to their parent compound by specific CYPs (31, 32) , and CYP activity is commonly assessed as EROD activity for CYPs 1A1 and 1A2, BROD for CYPs 2B1 and 3A, MROD for CYP 1A2 and PROD for CYPs 2B1 and 3B2.
Moltox provided historical QC results for 100 lots of Aroclor 1254-induced rat liver S9 and 19 lots of human liver S9. The rat liver S9 QC results contain enzymatic activity measured as EROD, BROD, MROD and PROD. An analysis of AROD activity data from the QC results of Moltox S9 lots demonstrates the dramatic upregulation of enzymatic activity associated with Aroclor 1254 treatment ( Table 1 ). In comparison, typical AROD specific activities (mean ± SE) for phenobarbital/β-naphthoflavone-induced rat liver S9 from Moltox are 5883.2 ± 520.8, 6525.2 ± 792.1, 833.2 ± 112.8 and 1649.0 ± 175.9 pmoles/min/mg protein for EROD, BROD, MROD and PROD, respectively (N = 16). Typical AROD specific activities (mean ± SE) for uninduced hamster liver S9 from Moltox, which is frequently used for the assessment of N-nitroso compounds and azo compounds, are 78.4 ± 21.4, 180.1 ± 36.8, 198.8 ± 52.8 and 12.8 ± 3.1 pmoles/min/mg protein for EROD, BROD, MROD and PROD, respectively (N = 6).
The Moltox QC sheets for human liver S9 contain enzymatic activity values expressed as EROD, BROD and MROD. Not surprisingly, the data for human S9 lots indicate that the levels of EROD, BROD and MROD are far lower in comparison to the Aroclorinduced rat liver S9 values summarised in Table 1 . Figure 1 illustrates mean AROD activity levels and their distributions for human liver S9 and Aroclor 1254-induced rat liver S9. The data show that mean levels of EROD, BROD and MROD activity are on average 55-, 52-and 16-fold greater in Aroclor 1254-induced rat liver S9 compared with human liver S9, respectively. The induced rat liver S9 activity values follow a normal distribution. Conversely, although the majority of human S9 lots varied very little, the data indicate that the distributions are positively skewed with outliers showing enzymatic activities that are 22.0-, 19.3-and 10.9-fold above the geometric mean for EROD, BROD and MROD, respectively.
Ames mutagenic activity comparison
Chemical data wherein more than ten potency observations based on human liver S9 in a particular Ames strain were found in the literature underwent a comparative analysis with induced rat liver results. Analysis of published mutagenic potency data indicates that metabolic activation by human liver S9 generally leads to lower values in comparison with those observed with induced rat liver S9 (Table 2, Figure 2 ). For example, the mean mutagenic potencies for the polycyclic aromatic hydrocarbons (PAHs) BaP and 3-MC were approximately 4-and 8-fold higher in TA100 when tested using Aroclor 1254-induced rat liver S9, respectively (Figure 2A and B) . The potencies of AFB1 in TA100 and TA98 are approximately 5-and 40-fold greater, respectively, when tested in the presence of Aroclor 1254-induced rat liver S9 ( Figure 2C and D) . In the presence of Aroclor 1254-induced rat liver S9, IQ yields TA98 potency values that are on average approximately 350-fold greater than those observed in the presence of human liver S9 ( Figure 2K) . Similarly, the TA98 potency of heterocyclic amines (HCAs) Trp-P2 and PhIP are approximately 200-and 8-fold greater, respectively, when tested in the presence of rat liver S9 treated with any inducer (Figure 2L and M) . It is interesting to note the considerable variability of the mutagenic potency data for both IQ and Trp-P2 when tested in the presence of human liver S9.
Unlike the mutagenic compounds discussed above, aromatic amines (AAs) such as 2-AA, 2-AF and 2-AAF, as well as the nitrosamine DMN, often yield mutagenic potency values generated in the presence of Aroclor 1254-induced rat liver S9 that are significantly lower than those observed with human liver S9. The mean mutagenic potency of 2-AA is approximately 40-fold higher when tested on TA100 with human liver S9, in comparison with Aroclor 1254-induced rat liver S9 results ( Figure 2F ). The mutagenic potency of 2-AF is on average 3-fold higher when tested on TA100 with human liver S9, in comparison with Aroclor 1254-induced rat liver S9 results (Figures 2G). For TA98, 2-AF mutagenic potency differences between induced rat and human S9 were not significant ( Figure 2H ). The average mutagenic potencies of 2-AAF on TA100 and TA98 are approximately 4-and 6-fold greater, respectively, in the presence of human liver S9 compared to Aroclor 1254-induced rat liver S9 ( Figure 2I and J) . Finally, the nitrosamine DMN also showed slightly higher mutagenic potency in the presence of human liver S9 in comparison with that observed in the presence of induced rat liver S9. The average mutagenic potency of DMN on strain YG7108 is approximately 2-fold higher in the presence of human liver S9 in comparison with hepatic S9 from rats treated with any inducer ( Figure 2E ).
With respect to the distribution of human S9 potency values for the aforementioned chemicals, it is interesting to note that the published values include several exceptional outliers and data points that impart a marked positive skew (i.e. exceptionally high human S9 results). These outliers relate to human liver S9 sources/lots employed in several published studies (Figure 2 ). One lot of human liver S9 in particular that was used in several studies by Hakura et al. (33) (34) (35) (i.e. lot HLS-14) yielded extremely high mutagenic potency values relative to the human liver S9 average ( Figure 2B , G, and M). The authors of those studies noted that this lot of human liver S9 showed exceptional enzymatic activity (e.g. EROD and CYP 3A4), and was obtained from an individual taking medication for asthma.
The survey of the literature also revealed a limited amount of mutagenic potency data for other compounds and mixtures. Cigarette smoke condensate, e.g. was found to yield TA1538 mutagenic potency with induced rat liver S9 that is 200-fold higher than human liver S9 (P = 0.002, N = 8). Similarly, 4-aminobiphenyl, a carcinogenic precursor to azo compounds, showed a 6-fold higher TA1538 mutagenic potency in the presence of induced rat liver S9 compared with human liver S9 (P = 0.02, N = 9). In addition, five observations of TA98 mutagenic potency for coal tar extract in the presence of human liver S9 had a mean mutagenic potency of 1.7 revertants/µg; less than 10% of the potency level observed with Aroclor 1254-induced rat liver S9 (i.e. 19.5 revertants/µg). Conversely, 1-nitropyrene results showed a significantly higher mutagenic potency (2.5-fold) in the presence of human liver S9 in comparison with induced rat liver S9 (P = 0.02, N = 5).
The relationship between enzyme activity and mutagenic potency was examined using AROD activity data and Ames test results obtained from Moltox QC sheets (Figure 3) . EROD activity is positively correlated with 2-AA mutagenic potency assessed in the presence of Aroclor 1254-induced rat S9. The 2-AA mutagenic potency appears to plateau when EROD activity is very high ( Figure 3A) . Despite the variations in the mutagenic potency of BaP across S9 lots, potency is also positively related to EROD activity ( Figure 3B ). In contrast, the QC sheet data indicate that there is no consistent empirical relationship between the mutagenic activity of positive controls and the EROD activity of human liver S9 lots. More specifically, as shown in Figure 3C and D, 2-AA and 6-AC mutagenic potency data are highly variable, and there is no significant relationship between mutagenic potency and human S9 EROD activity. The trends were similar for BROD, MROD and PROD (data not shown).
In addition to comparative assessments of mutagenic potency, we also investigated the influence of S9 source (i.e. human liver versus Aroclor 1254-induced rat liver) on test outcome (i.e. positive or negative). In other words, we used published results to assess the ability of a test system employing human liver S9 to successfully identify a known mutagen. Table 3 summarises the frequency of positive and negative outcomes for 11 mutagens. For the compounds and bacterial strains examined, the collected data show stark differences in test outcomes for 2-AAF and BaP on TA100. In both cases, more than 40% of the total responses obtained in the presence of human liver S9 failed to meet the criteria for a positive test outcome determination. In addition to the compounds listed in Table 3 The use of human liver S9 from an individual instead of pooled human liver S9 was also examined. Our survey of the literature, in addition to data supplied by Moltox, indicates that rat liver S9 is almost always prepared using pooled liver homogenates prepared using organs from numerous animals. Moltox confirmed that although S9 lots have been prepared using organs from as few as six animals and as many as 40-45 animals, lots of Aroclor-induced rat liver S9 prepared for retail sale are generally prepared from 25 to 40 livers (Moltox Inc., personal communication). Human liver S9 produced by Moltox for retail sale generally includes pooled liver homogenate from five individuals. In contrast, published studies have employed human liver S9 preparations from single donors, as well as lots prepared using livers from several donors. Although the published data are very limited, we compared mutagenicity results obtained with human liver S9 from a single donor with responses obtained using pooled lots of human liver S9 prepared with organs from several donors. Analysis of the available published data failed to reveal any significant difference between Ames mutagenic potency results obtained using pooled human liver S9 versus results obtained using S9 prepared from individual donor organs.
Effect of S9 concentration
Although data were limited, it was possible to analyse the correlation between mutagenic potency and the concentration of human S9 in mg protein/plate for AFB1, DMN, diethylnitrosamine (DEN), 2-AAF and IQ. There is a significant positive correlation between a Geometric mean derived from mutagenic potency values generated using Aroclor 1254-induced rat liver S9 only. b Geometric mean derived from mutagenic potency values generated using induced rat liver S9 prepared following treatment with any inducing agent. c NS, not significant at P < 0.05.
potency and S9 concentration for 2-AAF tested on TA98 (N = 36, F ratio = 19.2, P < 0.0001; data not shown); however, significant relationships were not found for any of the other chemicals examined (data not shown).
Mammalian cell data
A publication by Johnson et al. (25) , detailing an analysis that evaluated the utility of human liver S9 for the in vitro mammalian SCE and CA assays, recommended optimisation of an isocitrate dehydrogenase-mediated NADPH generating system and also noted that, to achieve positive results, higher concentrations of S9 and promutagens are required for human liver S9 in comparison with induced rat liver S9. For example, a concentration of 1.5% induced rat liver S9 was sufficient to yield a positive response for 20 µM BaP, whereas a concentration of 10% human liver S9 was necessary to elicit a positive response from 300 µM BaP. Cytotoxicity to mammalian cell lines and reduced sensitivity are known drawbacks associated with the use of human liver S9 (BioReliance, Covance Inc., personal communications). Due to the paucity of data in the published literature, additional data were experimentally generated to examine the utility of human liver S9 for in vitro genetic toxicity assessment with mammalian cell assays. Cytotoxicity to mammalian cell lines was observed for both human and induced rat liver S9. A lot of human liver S9 from Moltox (lot 2637) induced substantial cytotoxicity, measured as RPD, in three tested cell lines, L5178Y mouse lymphoma, CHO and human TK6, in the absence of promutagen exposure (data not shown). Severe toxicity was apparent with Moltox lot 2637 at a concentration of 2% in L5178Y cells and 4% for CHO and human TK6 cells (data not shown). Human liver S9 obtained from BD (lot 73024) appeared to be bacterially contaminated, but demonstrated little to no cytotoxicity in the three cell lines up to the maximum tested concentration of 10% (data not shown).
MN induction by BaP and 2-AAF was assessed in L5178Y mouse lymphoma cells exposed in the presence of an S9 mix containing either Aroclor 1254-induced rat liver S9 or human liver S9 (Figure 4) . Unlike Aroclor 1254-induced rat liver S9, the human liver S9 from BD lot 73024 did not lead to a significant induction in micronuclei following exposure to BaP at either of the tested S9 concentrations ( Figure 4A ). Conversely, human liver S9 from BD lot 73024 yielded a higher frequency of MN in response to 2-AAF exposure in comparison with Aroclor 1254-induced rat S9 ( Figure 4B ). The 2-AAF results also showed that induction of MN is enhanced when the cells are exposed in the presence of an increased concentration of human liver S9 (i.e. 10% versus 2%). It is important to note that higher concentrations of human S9 also led to higher cytotoxicity. A 10% concentration of BD human liver S9 lot 73024 yielded a reduction in survival, as measured by RPD, that exceeds the OECD test guideline (30) , and the cells may have suffered significant cell cycle delay leading to an underestimation of genotoxicity. MN induction could not be assessed with Moltox human S9 lot 2906, for either BaP or 2-AAF, due to severe cytotoxicity ( Figure 4C and 4D) . In all cases, human liver S9 was more cytotoxic than rat liver S9.
Human liver S9 usage survey
A survey of 24 members of the Mammalian Mutagenicity Society, a special interest group associated with the Japanese Environmental Mutagenesis Society, was conducted to gather information related to the use of human liver for test article screening. Most of the researchers surveyed had not used human liver S9, and the reasons given included (i) not needing to evaluate the genotoxicity of humanspecific metabolites (40.9% of respondents), (ii) using synthesised metabolites to assess genotoxicity (18.2% of respondents), (iii) poor reproducibility relative to rodent S9 (12.5% of respondents), (iv) lack of information regarding utility of human liver S9 (12.5% of respondents), (v) low enzyme activity (8.3% of respondents) and (vi) protocols that restrict the use of human material (4.5% of respondents). The general opinion of those that have not used human liver S9 was that there is poor reproducibility between lots, lower sensitivity relative to induced rat liver S9; and moreover, that the effectiveness of human-derived S9 for test article screening is relatively unknown. Only 29.2% of the individuals surveyed had used human liver S9 in an in vitro genotoxicity test. Of those who had used human liver S9, 85.7% only used S9 pooled from several (pooled) donors. The survey respondents revealed that human liver S9 was used for (i) measuring metabolite concentrations for an in vitro cytogenetic assay (85.7% of respondents), (ii) measuring metabolite concentrations for an Ames test (57.1% of respondents), (iii) genotoxicity assessment via the Ames test (42.9% of respondents), (iv) measuring metabolite concentrations for an MLA (42.9% of respondents), (v) genotoxicity assessment via and in vitro cytogenetic assay (28.6% of respondents) and (vi) genotoxicity assessment via the MLA (14.3% of respondents). In addition, respondents indicated that human liver S9 was used to (i) add to the weight of evidence given that previous tests using induced rat liver S9 were positive (42.9% of respondents), (ii) to catalyse the formation of a human metabolite that cannot be generated using rat liver S9 (28.6% of respondents), (iii) to assess human-specific metabolites (14.3% of respondents) and (iv) to compare results with human S9 to results obtained with bacteria expressing human CYPs (14.3% of respondents). Drawbacks to using human liver S9 were noted and these included (i) difficulty selecting concentrations for positive controls (57.1% of respondents), (ii) differences between lots of human liver S9 with respect to enzyme activity and test results (28.6% of respondents), (iii) requirement to design new quality control protocols (14.3% of respondents) and (iv) difficulty obtaining human liver S9 in a timely fashion (14.3% of respondents). Of the respondents that had used human liver S9, 14.3% reported obtaining a negative result with human S9 and a positive result with rodent S9. Interestingly, 14.3% of respondents reported instances where Ames tests for a particular compound were negative with both human and rat liver S9, but a CA test for the same compound yielded a positive result with human liver S9 and a negative result with rat liver S9. Of those who had used human liver S9, 85.7% stated that they would work with it again. Overall, 50% of respondents indicated that human liver S9 should be used in cases where the synthesis of the metabolite is difficult by any other means or the metabolite is human specific. Similarly, 50% of respondents stated that, as part of a weight of evidence approach, human liver S9 should be used to follow-up tests conducted using rat liver S9.
Discussion
Post-mitochondrial supernatants, more commonly known as S9, derived from mammalian liver are extensively used as sources of exogenous metabolic enzymes for in vitro genotoxicity assessment. Rat liver S9 obtained from chemically-induced animals is the most popular source of exogenous metabolic enzymes for routine in vitro testing. However, its relevance for detecting human mutagenic hazards has been called into question (36) . Indeed, S9 derived from human liver has become increasingly available in recent years, and at first glance, appears to offer the promise of an exogenous source of metabolic enzymes with improved relevance to humans. Through comparisons with the traditionally used induced-rat hepatic S9, this study sought to critically evaluate the utility of human liver S9 for identification of chemically-induced mutagenic hazards. This study is the first attempt to collect, collate and analyse mutagenic potency data from the published literature to assess the performance of human liver S9 in relation to induced rat liver S9 that has been routinely used for the past 40 years to identify and assess mutagenic hazards.
The most notable characteristic that immediately differentiates human liver S9 from the more conventionally used Aroclor 1254-induced rat liver S9 is its relatively low, variable and highly skewed enzymatic activity, as measured by AROD activity, and the concomitant highly variable mutagenic potency values. Conversely, relative to human liver S9, Aroclor 1254-induced rat liver S9 has extremely high, normally-distributed enzymatic activity measured by AROD activity, and generally yields less variable mutagenic potency values. Some variability in Ames mutagenic potencies may be due to inter-laboratory inconsistencies and differences between protocols (i.e. plate incorporation and pre-incubation); however, these sources of variability likely played a smaller role than inter-species enzyme activity differences.
The aforementioned variability in the enzymatic profiles of human liver S9 samples, relative to Aroclor-induced rat liver S9, would certainly be expected to affect the results of in vitro mutagenicity assessments. Indeed the data presented here, which included both published data and new experimental data, indicate that mutagenicity responses elicited in the presence of human liver S9 are often far lower than those observed with induced rat liver S9. This was observed for a variety of known mutagens that require different CYP isozymes. More specifically, the collected data revealed that the Salmonella mutagenic potency of PAHs, AFB1 and HCAs, which are converted to DNA reactive metabolites by CYP 1A1/1A2, CYPs 1A2/3A4, CYPs 1A1/1A2 and conjugation enzymes, respectively, are on average, substantially reduced when tested with human liver S9, relative to Aroclor-induced rat liver S9. The significant empirical relationships between mutagenic potency and the AROD activity levels of induced rat liver S9 supports the notion that the activity of CYP 1, 2 and 3 family isozymes alter the influence of different lots of induced rat liver S9 on mutagenic potency. In contrast, the data obtained from the Moltox QC sheets indicated that the ability of human liver S9 to convert chemical mutagens to DNA-reactive products is not empirically dependant on AROD levels. Unlike the mutagenic potency data for the aforementioned mutagens, AA results (i.e. 2-AF, 2-AAF and 2-AA) for both Salmonella mutagenicity and micronucleus induction in L5178Y mouse lymphoma cells indicate that responses obtained using human liver S9 can exceed those of induced rat liver S9.
A handful of investigations into the utility of human liver S9 can be found in the scientific literature. One of the first studies examining human liver S9 in the Ames test found that it was generally less active than phenobarbital-induced rat liver S9 for 20 known carcinogens, except for 2-AA, 2-AAF, 4-aminobiphenyl, 6-AC and AFB1, all of which produced qualitatively similar results regardless of the S9 used (37) . This early work only examined a human liver S9 preparation from one individual; however, a later study by Beaune et al. (38) investigating 10 different human liver S9 samples yielded additional evidence that human liver S9 is more active towards certain classes of carcinogens. Beaune et al. (38) found that the AAs 2-AA and 2-AF are far more mutagenic when activated by human liver S9 than by uninduced or Aroclor-induced rat liver S9. In contrast, human liver S9 was found to be far less effective for the PAH 3-MC than Aroclor-induced rat liver S9. Similarly, in the large-scale analysis of published Salmonella mutagenic potency data presented herein, it was observed that human liver S9 yielded higher mutagenic potencies for AAs, and lower mutagenic potencies for PAHs.
The lower mutagenicity of AAs in the presence of Aroclorinduced rat liver S9, relative to human liver S9, appears to be due to interspecies differences in hepatic levels and functions of CYP 1A1 and CYP 1A2. Rat hepatic CYP 1A1 is responsible for C-oxidation, leading to the ring-hydroxylation and subsequent detoxification of AAs, and rat hepatic CYP 1A2 is responsible for N-oxidation, leading to activation of AAs to DNA-reactive metabolites. Humans have extremely low levels of hepatic CYP 1A1, thus AAs preferentially undergo N-oxidation through CYP 1A2 in the liver, leading to AA activation and mutagenic activity (39, 40) . Induction by chemicals such as Aroclor 1254 dramatically elevates the activity of rat hepatic CYP 1A1, thus the production of reactive AA metabolites is decreased relative to humans and uninduced rats (38) . The inverse correlation of increased CYP activity and lower AA mutagenicity has been observed in several studies (38, 41, 42) . Indeed, the analyses presented here suggest that the mutagenic activity of AAs can decline when Aroclor-induced rat liver S9 EROD activity exceeds 1 nmole/ min/mg protein ( Figure 3A) .
Unlike AAs, PAHs appear to be much less mutagenic with human liver S9 than with induced rat liver S9. A high frequency of negative results was obtained for both BaP and 3MC in the presence of human liver S9, but not rat liver S9 (Table 3) . Frequent negatives for PAHs tested with human liver S9 are likely the result of the aforementioned low expression of CYP1A1, a key enzyme in PAH metabolism and activation, in human liver relative to rat liver. Unlike the human liver, human lungs have relatively high levels of CYP1A1, thus PAH exposure has been shown to increase the risk of lung cancer (43) . Additionally, human liver S9 does not benefit from the approximately 120-fold boost in EROD (i.e. CYP 1A1 and CYP 1A2) activity afforded to rat liver S9 by Aroclor induction.
In comparison to bacterial mutagenesis studies, relatively few published studies have used human liver S9 for in vitro mammalian cell genetic toxicity assays (25, (44) (45) (46) (47) (48) . Johnson et al. conducted a comprehensive investigation regarding the use of human and Aroclor 1254-or phenobarbital/β-naphthoflavone-induced rat liver S9 to assess the clastogenicity of BaP, AFB1, DMN, DEN and 2-AAF, compounds that require different CYP isozymes for activation. More specifically, genotoxic activity was assessed using the SCE and CA induction assays in CHO cells, and with the exception of BaP, the results showed that human liver S9 was capable of converting all tested chemicals to mutagenic metabolites that induce CAs. Additionally, it was observed that a stronger CA response for 2-AAF was obtained using human liver S9, relative to induced rat liver S9, echoing the results obtained in bacterial tests, and the results obtained herein. It is important to note that the Johnson et al. (25) study utilised an isocitrate dehydrogenase-based NADPH generation system, observing that it is an essential component of an optimised S9 cofactor mix; and moreover, increased the S9 concentration to maximise the observed mutagenic response. This cofactor mix is an alternative to the cofactor mix concentrations initially described by Ames et al. (24) and Maron and Ames (26) , which all bacterial mutagenesis assays analysed in this study utilised, with very few exceptions.
The current study is the first to assess the utility of human liver S9 for the in vitro micronucleus assay. Similar to the aforementioned bacterial and mammalian cell test results, the results obtained indicate that human liver S9 was not effective at converting BaP to a clastogenic metabolite, but it was more effective than Aroclor 1254-induced rat liver S9 at converting 2-AAF to a metabolite that induces micronucleus formation (Table 2, Figure 2A , I and J). It was observed that higher concentrations of human liver S9 (i.e. 10% instead of 2%) yielded higher MN frequencies in L1587Y cells treated with 2-AAF; a similar observation was made by Johnson et al. (25) . It is important to note that increasing S9 concentrations can be problematic since higher S9 concentrations can lead to increased extra-cellular protein binding of active metabolites, thus lowering genotoxicity.
Significant cytotoxicity was observed with Moltox human liver S9 lot 2637 tested using three commonly used cell lines; CHO and TK6 cells were less sensitive to human liver S9-induced cytotoxicity than L5178Y cells. However, this severe cytotoxicity was not seen for all tested lots, and BD lot 73024 exhibited far less cytotoxicity in the three cell lines examined. These limited data suggest that mammalian cell cytotoxicity will limit the utility of human liver S9 for routine assessment of in vitro genetic toxicity. The cytotoxicity of human liver S9 may be attributable to NADP-induced lipid peroxidation and the production of reactive oxygen species (49) . However, this contention does not explain why the same level of cytotoxicity is not observed with induced rat liver S9. It is possible that the longer cold ischemia time for human subjects relative to experimental rodents (i.e. chilling time in the absence of blood supply) results in differential production of reactive oxygen species in respective S9 fractions. If so, the NADPH-generating cofactor mixtures may need to be further optimised to permit effective use of human liver S9 in mammalian cell assays. Inter-species variability may also be playing a role, and further investigations would be required to delineate the processes underlying the cytotoxicity of human liver S9.
Medications, alcohol use, smoking status and diet can influence metabolic enzyme activity, and thus, modulate the ability of S9 preparations to convert test compounds to DNA-reactive products. Drug-induced inhibition and induction of human metabolic enzymes is extremely well documented (50) . For example, phenobarbital, a commonly-prescribed antiepileptic drug, is a potent inducer of several CYPs via CAR/PXR agonism (51) . Ethanol is an effective CYP 2E1 inducer; thus, chronic alcoholism can lead to an increased risk of in vivo mutagenesis through the CYP2E1-mediated metabolism of promutagens such as nitrosamines (52, 53) . Smoking and occupational exposures to combustion by-products can upregulate CYP 1A1, 1A2 and 1B1 activity through AhR agonism (54) (55) (56) , and lastly, some common foods, such as cruciferous vegetables, charred meat, grapefruit and garlic, contain compounds that can significantly increase or decrease the activity of selected metabolic enzymes (57) (58) (59) (60) .
The potential effects of therapeutic products were apparent in our review and analysis. Hakura et al. (33) (34) (35) noted large interindividual variations between human liver S9 preparations, and described one S9 sample in particular, dubbed HLS-014, that elicited Salmonella mutagenicity responses for 13 known mutagenic carcinogens that were equal to or greater than responses elicited in the presence of PB/BF-induced rat liver S9. Additional analyses indicated that the level of total CYP protein in the HLS-014 S9 sample was much greater in comparison with all other S9 lots examined; moreover, the level of CYP3A4 activity in HLS-014 was exceptionally high. The unusually high activity of HLS-014 was thought to be linked to the human donor's asthma medication, which may act as a receptor agonist (33) (34) (35) . Not surprisingly, our meta-analysis of published Salmonella mutagenicity data, which includes data from Hakura et al. (33) (34) (35) , revealed high variability in human S9 enzymatic activities (e.g. AROD activity levels), as well as mutagenicity responses to 3-MC, 2-AF and PhIP that include noteworthy outliers.
The human liver S9 lots prepared by Moltox, which were used in the reviewed studies and our mammalian MN induction assessments, include both male and female organ donors, of a wide range of ages. Although there is insufficient data to assess the influence of age or sex on the ability of human liver S9 lots to activate promutagens, the literature indicates that the activity of xenobiotic metabolising enzyme genes and enzyme activity levels can vary with sex and age. For example, a transcriptional profiling study of 112 female and 112 male human livers revealed that the expression of 40 xenobiotic metabolism-related genes is significantly influenced by sex (61) . Enzyme activity levels gradually increase during the first year of life (62), although age-related variability in adulthood is considerably more subtle. Nevertheless, CYP 1A2, 2D6 and 2E1 activities in adulthood decrease slightly with age (15) .
Genotypic variations in the genes that encode xenobiotic metabolising enzymes (i.e. Phase I and II) include numerous single nucleotide polymorphisms (SNPs) that are over-or under-represented in certain ethnic groups. For example, several members of the CYP 2 family, such as CYP 2D6, are highly polymorphic in humans (63) , with poor, intermediate, extensive and ultrarapid metabolisers present to different extents in different ethnic groups. For example, the CYP 2D6 PM phenotype is far more prevalent among Caucasians than Asians, and the ultrarapid metaboliser phenotype is predominant among Middle Eastern populations (64) , with more rapid metabolism being associated with an increased risk of adverse effects attributable to increased production of DNA-reactive metabolites. N-acetyltransferase 2 (NAT2), a phase II enzyme vital to the activation and detoxification of arylamines, is another example of a metabolic enzyme that is highly polymorphic in humans, with fast, slow and intermediate acetylator phenotypes being differentially prevalent in different ethnic groups (65) . The slow aceylator phenotype, which is less common in people of East Asian descent, has been linked to an increased overall risk of bladder cancer (66) . Unfortunately, commercially available human liver S9, which is predominantly prepared from Caucasian organ donors, cannot effectively reflect human metabolic diversity. Thus, the average pooled human liver S9 preparation is unlikely to be able to capture the full spectrum of activities in human xenobiotic metabolising enzymes.
The aforementioned variability in human xenobiotic metabolism is well documented, and known to be linked to genetic polymorphisms, environmental factors (e.g. occupation, tobacco smoking, diet, therapeutic product use, etc.), age and sex. Thus, with respect to an individual's ability to convert chemical mutagens into DNAreactive metabolites, it is reasonable to expect a great deal of variation in human sensitivity to mutagenic effects, and this variability suggests that human liver S9 prepared from individual organs cannot be reliably employed to identify mutagenic hazards. Indeed, data collected and presented herein indicate that use of human liver S9 can contribute to an inability to detect known mutagenic carcinogens such as BaP, 3-MC and PhIP (Table 3) . It has been suggested that high-activity human liver S9 samples, such as the aforementioned HLS-014, and S9 with average activity, such as pooled S9, should each be used for effective identification of human mutagenic hazards (67) . However, the results presented herein reveal that even pooled human liver S9 can yield negative responses for a known mutagenic carcinogen. On the other hand, there is evidence to suggest that some positive genotoxicity results obtained using rat liver S9 may have limited relevance to humans due to the production of ratspecific metabolites that are not produced in humans. Interestingly, a study that analysed metabolite profiles of 16 drugs generated using Aroclor-induced rat liver S9 and pooled human liver S9 showed that metabolites generated by human liver S9 were generally also generated by induced rat liver S9. However, rat liver S9 generally produced substantially elevated levels of metabolites and consumed far more of the parent compound (68) .
The aforementioned survey of Japanese laboratories routinely conducting genetic toxicity assessments revealed that some researchers employ Aroclor-induced rat liver S9 for compound screening, with targeted follow-ups employing human-derived S9, where appropriate. Although this survey was small, it provides an indication of the general opinions regarding the use of human liver S9 for genetic toxicity assessment. The survey also revealed that researchers recognise several drawbacks related to the use of human liver S9; notably, lower sensitivity and lot-to-lot variability. Indeed, the variability of human liver S9, and the concomitant risk of false negatives, suggests that chemically-induced rat liver S9 is effective and pragmatic, albeit conservative, for identifying chemical mutagens. Targeted follow-up studies with human-derived S9 can be used to provide data regarding interspecies differences in the metabolic activation of a given chemical, as well as to investigate the relevance of a genotoxicity result for human hazard identification.
In conclusion, despite the potential for increased human relevance, S9 preparations from human livers should not be solely used for in vitro genotoxicity assessment. Rat liver S9 is more likely to correctly identify mutagens, and limit the likelihood of undesirable false negative results. Additionally, the ability of human liver S9 to generate DNA-reactive metabolites does not appear to be dependent on AROD levels, and the enzymatic attributes of human liver S9 that contribute to its ability to convert chemical test articles to DNA-reactive metabolites remain unknown. Nevertheless, human liver S9 may be very useful for confirmatory assays that follow those employing induced rat liver S9. This is especially true for classes of chemicals where species-specific differences in metabolism are known or suspected (e.g. AAs).
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